WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), announced that it will conduct a conference call and audio webcast today at 10:00 a.m. Eastern Daylight Time regarding the company’s product development alliance with GlaxoSmithKline, which was announced earlier this morning. Participants from Targacept will include J. Donald deBethizy, Ph.D., President and Chief Executive Officer; Alan A. Musso, Vice President and Chief Financial Officer; and Jeffrey P. Brennan, Vice President, Business and Commercial Development. Mark Strobeck, Vice President, Drug Discovery Transactions, GlaxoSmithKline, will also participate.
